The 3 most recent market catalysts affecting $ACHV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 65
Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
Achieve Life Sciences has established an At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of its common stock through Jefferies. This is a common…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Initiates Coverage On Achieve Life Sciences with Overweight Rating, Announces Price Target of $13
Morgan Stanley analyst Maxwell Skor initiated coverage on Achieve Life Sciences (ACHV) with an Overweight rating and a $13 price target. This is a significant event for ACHV as new…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 95
Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
Achieve Life Sciences (ACHV) reported a Q2 EPS of $(0.80), which was a substantial miss compared to the analyst estimate of $(0.16). This 400% deviation from expectations, coupled …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.